FDA experts could remove Avandia restrictions; Pfizer loses patent on Viagra in U.K.;

@FiercePharma: In which hep C drugs Incivek and Victrelis go from hit to dud in two years. Report | Follow @FiercePharma

@EricPFierce: Dr. Reddy's, Fujifilm pull plug on Japanese joint venture. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Sun Pharma eyeing takeover of Sweden's Meda. Story | Follow @CarlyHFierce

> An FDA panel this week returns to the question of restrictions that the agency imposed on GlaxoSmithKline's ($GSK) diabetes drug Avandia. Story

> Pfizer ($PFE) loses patent protection on Viagra in the U.K. this month. Story

> A recent study found that 83% of cancer doctors report they have had to deal with shortages of oncology drugs and that it has almost affected treatment of their patients. Report

> The EU's Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Union approve Lonquex for the reduction of neutropenia, Teva Pharmaceutical Industries ($TEVA) reported Monday. More

> A study released at ASCO said that an inexpensive test using vinegar reduced cervical cancer rates significantly. Report

Medical Device News

@FierceMedDev: Mayo Clinic: Metabolomics could be key to early Alzheimer's blood Dx test. Article | Follow @FierceMedDev

@DamianFierce: Patient selection, biomarkers are key to cancer R&D, Quintiles says. Story | Follow @DamianFierce

@MichaelGFierce: Medtronic triggers summer PMA process for drug-eluting balloon. More | Follow @MichaelGFierce

> WHO approves low-tech Israeli circumcision device. News

> Medtronic triggers summer PMA process for drug-eluting balloon. Article

> Mayo Clinic: Metabolomics could be key to early Alzheimer's blood Dx test. More

> Cochlear downgrades profit forecast as clients await next-gen hearing aid. Story

Biotech News

@FierceBiotech: PR: 1st clinical data presented with ImmunoGen's IMGN853, potential new ovarian cancer therapy. Release | Follow @FierceBiotech

@JohnCFierce: GlaxoSmithKline grabs PhII rheumatoid arthritis drug in MorphoSys deal. Article | Follow @JohnCFierce

@RyanMFierce: Monday at ASCO marked by bad news from $SNY, $LLY after feel-good weekend for $MRK, $BMY. | Follow @RyanMFierce

@EmilyMFierce: New agent stops replication of hep C virus in preclinical studies. Article | Follow @EmilyMFierce

> Boehringer delivers small survival benefit for lung cancer patients. Story

> Clovis soars on upbeat signs of efficacy for targeted cancer drugs. News

> ASCO confab highlights immunotherapies, 'breakthrough' drugs and small victories. More

CRO News

> Quintiles: Patient selection, biomarkers key to cancer R&D. Report

> Unither buys UCB's NY plant. Item

> DKSH ups South Korean presence. Story

> QPS teams with Hepregen for DMPK. More

> UPM buys Pfizer's TN plant, snags CMO deal. Article

Biotech IT News

> Software-backed MTI system spots breast tumors. Item

> OpGen teams with bioinformatics outfit to combat outbreaks. Story

> BT and Accelrys deepen ties for cloud computing in life sciences. Report

> Eli Lilly backs mobile app for cancer docs. News

> Boehringer, Eli Lilly aim to educate diabetics with iPad game. Article

And Finally... India's government issued a statement today defending the domestic generic drug supply as safe in the face of growing concerns after enforcement actions by U.S. regulators against Ranbaxy Laboratories and Wockhardt. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.